Medpace Holdings, Inc.
MEDP
Positions held
Your positionsMEDP isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Medpace Holdings, Inc. operates in the growing diagnostics and research sector, which is driven by increasing demand for clinical trials and drug development services.
- In 2026-Q2, Medpace reported a revenue of $707.331 million, maintaining consistent performance with no growth decline from the previous quarter.
- The company's gross margin improved to 28.5% in 2026-Q2, up from 27.8% in the prior quarter.
- Despite its growth potential, Medpace's current ratio stands at 0.732, indicating potential liquidity concerns.
- The trailing P/E ratio is 35.4, suggesting that the stock may be overvalued compared to its earnings growth rate.
- In 2023, Medpace's net income was $282.81 million, which is significantly lower than the projected growth in revenue for upcoming years.
Fundamentals
| Market cap | $16.82B | Enterprise value | $16.46B | Trailing P/E | 35.39 | Forward P/E | 31.20 |
| PEG | 2.87 | Price / book | 38.77 | Beta | 1.18 | Dividend yield | 0.00% |
| Revenue growth | 17.2% | Earnings growth | 37.1% | Gross margin | 72.4% | Operating margin | 20.8% |
| Profit margin | 17.7% | ROE | 1.6% | ROA | 20.1% | Debt / equity | 0.33 |
| Current ratio | 0.73 | Free cash flow | $510.40M | Analyst recommendation | hold | Mean target | $594.54 |
| 52w high | $677.90 | 52w low | $373.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $707M | $707M | $708M | $660M | $603M | — |
| Op margin | 20.8% | 20.0% | 21.6% | 21.5% | 20.9% | — |
| Net income | $121M | $124M | $135M | $111M | $90.3M | — |
| Gross margin | 28.5% | 27.8% | 29.0% | 29.8% | 29.8% | — |
| Gross profit | $202M | $196M | $205M | $197M | $180M | — |
| Operating income | $147M | $142M | $153M | $142M | $126M | — |
- Revenue +0% vs prior quarter ($707M vs $707M).
- Gross margin 28.5% (was 27.8% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $2.5B | $2.1B | $1.9B | $1.5B |
| Op margin | 21.1% | 21.2% | 17.9% | 19.1% |
| Net income | $451M | $404M | $283M | $245M |
| Gross margin | 30.1% | 31.1% | 27.8% | 29.6% |
| Gross profit | $761M | $656M | $525M | $432M |
| Operating income | $535M | $447M | $337M | $279M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
2026-10-05 · 1 Momentum Stock Worth Investigating and 2 Facing Headwinds
2026-10-01 · Medpace Holdings Insider Sold Shares Worth $30,320,929, According to a Recent SEC Filing
2026-09-30 · UBS Upgrades Medpace Holdings to Neutral From Sell, Adjusts Price Target to $673 From $405
2026-09-29 · Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
2026-09-29 · Medpace Holdings Insider Sold Shares Worth $1,589,941, According to a Recent SEC Filing
2026-09-28 · CON or MEDP: Which Is the Better Value Stock Right Now?
2026-09-23 · 3 Market-Beating Stocks with Promising Prospects
2026-09-22 · Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
2026-09-22 · Projected EPS and Revenue Gains Might Change The Case For Investing In Medpace Holdings (MEDP)
2026-09-22 · Medpace Holdings (MEDP) Nears Earnings, Is The Stock Fully Valued?
2026-09-21 · Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Price (daily)
Full chart · RSI · MACD · patterns